| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
AMPA receptor (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) [1][2]
|
|---|---|
| ln Vitro |
- 1-BCP is a centrally active modulator of AMPA receptor-gated currents. In voltage-clamped rat hippocampal neurons, 1-BCP (10, 30 μM) dose-dependently potentiated AMPA-induced inward currents, increasing the peak current amplitude by ~35% (10 μM) and ~60% (30 μM) compared with the control group (detected by patch-clamp technique) [1]
- 1-BCP (1, 10, 100 μM) selectively potentiated AMPA-induced [³H]-norepinephrine release in rat hippocampal slices. At 10 μM, it increased the release by ~40% without affecting kainate or NMDA-induced neurotransmitter release (detected by radioligand assay) [2] - 1-BCP did not alter the affinity of AMPA for its receptor but prolonged the decay time of AMPA receptor-gated currents, indicating a modulatory effect on receptor desensitization or deactivation [1] |
| ln Vivo |
- 1-BCP exhibited memory-enhancing activity in rats. Behavioral tests (passive avoidance task) showed that intraperitoneal injection of 1-BCP (5, 10 mg/kg) significantly prolonged retention latency compared with the control group, indicating improved memory consolidation [2]
|
| Enzyme Assay |
- AMPA receptor-gated current recording: Rat hippocampal neurons were cultured for 7-14 days and voltage-clamped at -60 mV using the whole-cell patch-clamp technique. 1-BCP (10, 30 μM) was preincubated with neurons for 5 minutes, followed by application of AMPA (10 μM). Inward currents were recorded, and peak amplitude and decay time were analyzed [1]
- Neurotransmitter release assay: Rat hippocampal slices were prepared and preincubated with [³H]-norepinephrine for 60 minutes. Slices were then treated with 1-BCP (1-100 μM) and stimulated with AMPA (50 μM). The released [³H]-norepinephrine in the supernatant was quantified by liquid scintillation counting [2] |
| Cell Assay |
- Hippocampal neuron culture and patch-clamp assay: Hippocampi were dissected from neonatal rats, dissociated into single neurons, and seeded on poly-L-lysine-coated coverslips. After 7-14 days of culture, neurons were used for patch-clamp recording. 1-BCP was applied to the bath solution, and AMPA-induced currents were measured to evaluate the modulatory effect [1]
- Hippocampal slice neurotransmitter release assay: Rat brains were rapidly removed, and hippocampal slices (400 μm) were prepared. Slices were incubated in oxygenated Krebs-Ringer buffer, loaded with [³H]-norepinephrine, and treated with 1-BCP and AMPA. Radioactivity in the supernatant was counted to determine neurotransmitter release level [2] |
| Animal Protocol |
- Memory enhancement model: Adult rats were randomly divided into control and 1-BCP treatment groups (5, 10 mg/kg). 1-BCP was dissolved in sterile saline and administered via intraperitoneal injection 30 minutes before the training phase of the passive avoidance task. Twenty-four hours after training, the retention test was performed, and retention latency was recorded to assess memory function [2]
|
| References | |
| Additional Infomation |
1,3-Benzadioxopenten-5-yl(1-piperidinyl)methyl ketone is an N-acylpiperidine compound. 1-BCP is a synthetic small molecule compound with central nervous system activity [1][2]. Its core mechanism involves selective regulation of AMPA receptors: enhancing AMPA receptor gating currents and increasing AMPA-induced neurotransmitter release in the hippocampus, thereby enhancing memory [1][2]. 1-BCP is selective for AMPA receptors without affecting other glutamate receptor subtypes (algae receptors, NMDA receptors), suggesting its potential as a tool for studying AMPA receptor function and as a candidate drug for treating memory-related neurological disorders [1][2].
|
| Molecular Formula |
C13H15NO3
|
|---|---|
| Molecular Weight |
233.26300
|
| Exact Mass |
233.105
|
| CAS # |
34023-62-6
|
| PubChem CID |
1370
|
| Appearance |
White to off-white solid powder
|
| Density |
1.256g/cm3
|
| Boiling Point |
406.9ºC at 760mmHg
|
| Flash Point |
199.9ºC
|
| Index of Refraction |
1.587
|
| LogP |
1.979
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
17
|
| Complexity |
288
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
BXBNADAPIHHXJQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H15NO3/c15-13(14-6-2-1-3-7-14)10-4-5-11-12(8-10)17-9-16-11/h4-5,8H,1-3,6-7,9H2
|
| Chemical Name |
1,3-benzodioxol-5-yl(piperidin-1-yl)methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~428.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2871 mL | 21.4353 mL | 42.8706 mL | |
| 5 mM | 0.8574 mL | 4.2871 mL | 8.5741 mL | |
| 10 mM | 0.4287 mL | 2.1435 mL | 4.2871 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
